Financials in GBp. Standardized financial statements.
A compact view of how Hikma Pharmaceuticals PLC turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | £3.42B | £3.13B | £2.88B | £2.52B | £2.55B | £2.34B | £2.21B | £2.07B | £1.94B | £1.95B |
| Revenue Growth? | +9.3% | +8.8% | +14.2% | -1.4% | +9.1% | +6.1% | +6.6% | +6.9% | -0.7% | 0.0% |
| Cost of Revenue? | £2.05B | £1.71B | £1.47B | £1.25B | £1.25B | £1.13B | £1.11B | £1.07B | £1.02B | £1.00B |
| Gross Profit? | £1.37B | £1.42B | £1.41B | £1.26B | £1.30B | £1.21B | £1.10B | £1.00B | £915.00M | £950.00M |
| Gross Margin? | +40.0% | +45.3% | +48.9% | +50.3% | +51.0% | +51.8% | +49.8% | +48.5% | +47.3% | +48.7% |
| Operating Expenses? | £732.04M | £803.00M | £1.04B | £976.00M | £715.00M | £621.00M | £578.00M | £673.00M | £1.60B | £694.00M |
| Operating Income? | £637.09M | £612.00M | £367.00M | £591.00M | £634.00M | £540.00M | £486.00M | £428.00M | £336.00M | £401.00M |
| EBITDA? | £853.54M | £787.00M | £791.00M | £485.00M | £744.00M | £631.00M | £584.00M | £527.00M | £554.00M | £506.00M |
| Income Before Tax | £529.89M | £455.00M | £281.00M | £233.00M | £544.00M | £558.00M | £491.00M | £293.00M | -£738.00M | £210.00M |
| Income Tax Expense | £114.35M | £93.00M | £89.00M | £42.00M | £124.00M | £128.00M | £4.00M | £8.00M | £101.00M | £52.00M |
| Net Income? | £410.43M | £359.00M | £190.00M | £188.00M | £421.00M | £431.00M | £486.00M | £282.00M | -£843.00M | £155.00M |
| EPS? | £1.86 | £1.61 | £0.85 | £0.84 | £1.82 | £1.83 | £2.01 | £1.17 | £-3.51 | £0.67 |
| Diluted EPS? | £1.84 | £1.61 | £0.85 | £0.84 | £1.81 | £1.81 | £2.00 | £1.17 | £-3.51 | £0.66 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality